Skip to main content

Table 1 Demographics and baseline characteristics stratified by age group

From: Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials

Aged < 40 years

Placebo (n= 600)

Erenumab 70 mg (n= 517)

Erenumab 140 mg (n= 383)

Total (N= 1500)

Age, mean (SD)a

30.8 (5.8)

30.2 (6.1)

30.6 (5.7)

30.5 (5.9)

Female, n (%)

495 (82.5)

439 (84.9)

316 (82.5)

1250 (83.3)

Race, n (%)

 Asian

161 (26.8)

172 (33.3)

116 (30.3)

449 (29.9)

 White

384 (64.0)

295 (57.1)

233 (60.8)

912 (60.8)

BMI (kg/m2), mean (SD)

26.1 (6.0)

26.1 (6.0)

25.9 (6.0)

26.0 (7.0)

MMDs, mean (SD)

10.4 (5.2)

9.7 (4.7)

10.2 (5.4)

10.1 (5.1)

MMDs, categories, n (%)

 8–14 MMDs

279 (46.5)

238 (46.0)

181 (47.3)

698 (46.5)

 ≥ 15 MMDs

96 (16.0)

67 (13.0)

46 (12.0)

209 (13.9)

Medication overuse, n (%)b

 Yes

37 (6.2)

29 (5.6)

23 (6.0)

89 (5.9)

 No

77 (12.8)

48 (9.3)

42 (11.0)

167 (11.1)

PPTF, n (%)

0

363 (60.5)

337 (65.2)

211 (55.1)

911 (60.7)

 1

102 (17.0)

96 (18.6)

70 (18.3)

268 (17.9)

 2

48 (8.0)

41 (7.9)

46 (12.0)

135 (9.0)

 ≥ 3

87 (14.5)

43 (8.3)

56 (14.6)

186 (12.4)

Framingham cardiovascular risk factors

Cigarette use, n (%)

 Current

30 (5.0)

36 (7.0)

26 (6.8)

92 (6.1)

 Former

33 (5.5)

28 (5.4)

10 (2.6)

71 (4.7)

 Never

195 (32.5)

177 (34.2)

108 (28.2)

480 (32.0)

 Unknown

342 (57.0)

276 (53.4)

239 (62.4)

857 (57.1)

Diabetes, n (%)

3 (0.5)

4 (0.8)

3 (0.8)

10 (0.7)

Hypertension, n (%)

39 (6.5)

22 (4.3)

18 (4.7)

79 (5.3)

Total cholesterol (mmol/L), mean (SD)

4.6 (1.0)

4.6 (0.8)

4.6 (1.0)

4.6 (0.8)

HDL cholesterol (mmol/L), mean (SD)

1.4 (0.4)

1.4 (0.4)

1.4 (0.4)

1.4 (0.4)

Systolic BP (mmHg), mean (SD)

116.9 (11.9)

115.4 (11.4)

115.7 (11.6)

116.1 (12.0)

Coronary artery disease, n (%)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Cerebrovascular or peripheral artery disease, n (%)

1 (0.2)

0 (0.0)

2 (0.5)

3 (0.2)

Aged 40–49 years

Placebo (n = 426)

Erenumab 70 mg (n = 361)

Erenumab 140 mg (n = 278)

Total (N = 1065)

Age, mean (SD)

44.4 (2.8)

44.4 (2.8)

44.6 (2.8)

44.4 (2.8)

Female, n (%)

361 (84.7)

303 (83.9)

237 (85.3)

901 (84.6)

Race, n (%)

 Asian

78 (18.3)

82 (22.7)

45 (16.2)

205 (19.2)

 White

317 (74.4)

259 (71.7)

224 (80.6)

800 (75.1)

BMI (kg/m2), mean (SD)

26.6 (5.3)

26.3 (5.3)

26.1 (4.9)

26.4 (5.2)

MMDs, mean (SD)

10.3 (4.7)

9.7 (4.4)

10.9 (4.8)

10.2 (4.6)

MMDs, categories, n (%)

 8–14 MMDs

224 (52.6)

186 (51.5)

141 (50.7)

551 (51.7)

 ≥ 15 MMDs

63 (14.8)

40 (11.1)

52 (18.7)

155 (14.6)

Medication overuse, n (%)b

 Yes

42 (9.9)

31 (8.6)

27 (9.7)

100 (9.4)

 No

49 (11.5)

33 (9.1)

43 (15.5)

125 (11.7)

PPTF, n (%)

 0

182 (42.7)

200 (55.4)

122 (43.9)

504 (47.3)

 1

90 (21.1)

67 (18.6)

36 (12.9)

193 (18.1)

 2

68 (16.0)

47 (13.0)

61 (21.9)

176 (16.5)

 ≥ 3

86 (20.2)

47 (13.0)

59 (21.2)

192 (18.0)

Framingham cardiovascular risk factors

Cigarette use, n (%)

17 (4.0)

20 (5.5)

9 (3.2)

46 (4.3)

 Current

39 (9.2)

32 (8.9)

18 (6.5)

89 (8.4)

 Former

135 (31.7)

145 (40.2)

75 (27.0)

355 (33.3)

 Never

235 (55.2)

164 (45.4)

176 (63.3)

575 (54.0)

 Unknown

9 (2.1)

8 (2.2)

3 (1.1)

20 (1.9)

Diabetes, n (%)

55 (12.9)

41 (11.4)

35 (12.6)

131 (12.3)

Hypertension, n (%)

17 (4.0)

20 (5.5)

9 (3.2)

46 (4.3)

Total cholesterol (mmol/L), mean (SD)

5.1 (0.9)

5.0 (0.9)

5.0 (0.9)

5.0 (0.9)

HDL cholesterol (mmol/L), mean (SD)

1.5 (0.4)

1.5 (0.4)

1.5 (0.4)

1.5 (0.4)

Systolic BP (mmHg), mean (SD)

120.0 (12.4)

119.0 (13.0)

119.6 (13.2)

119.5 (12.8)

Coronary artery disease, n (%)

2 (0.5)

1 (0.3)

0 (0.0)

3 (0.3)

Cerebrovascular or peripheral artery disease, n (%)

4 (0.9)

1 (0.3)

1 (0.4)

6 (0.6)

Aged 50–59 years

Placebo (n = 263)

Erenumab 70 mg (n = 216)

Erenumab 140 mg (n = 158)

Total (N = 637)

Age, mean (SD)

53.9 (2.8)

53.9 (2.8)

53.7 (2.8)

53.8 (2.8)

Female, n (%)

220 (83.7)

178 (82.4)

133 (84.2)

531 (83.4)

Race, n (%)

 Asian

36 (13.7)

23 (10.6)

15 (9.5)

74 (11.6)

 White

208 (79.1)

179 (82.9)

128 (81.0)

515 (80.8)

BMI (kg/m2), mean (SD)

25.8 (5.3)

26.8 (5.3)

25.7 (4.9)

26.1 (5.2)

MMDs, mean (SD)

10.9 (5.6)

10.2 (4.9)

10.8 (5.1)

10.6 (5.3)

MMDs, categories, n (%)

 8–14 MMDs

117 (44.5)

98 (45.4)

67 (42.4)

282 (44.3)

 ≥ 15 MMDs

51 (19.4)

37 (17.1)

39 (24.7)

127 (19.9)

Medication overuse, n (%)b

 Yes

31 (11.8)

15 (6.9)

25 (15.8)

71 (11.1)

 No

30 (11.4)

28 (13.0)

22 (13.9)

80 (12.6)

PPTF, n (%)

 0

115 (43.7)

101 (46.8)

67 (42.4)

283 (44.4)

 1

55 (20.9)

54 (25.0)

21 (13.3)

130 (20.4)

 2

40 (15.2)

25 (11.6)

21 (13.3)

86 (13.5)

 ≥ 3

53 (20.2)

36 (16.7)

49 (31.0)

138 (21.7)

Framingham cardiovascular risk factors

Cigarette use, n (%)

 Current

14 (5.3)

11 (5.1)

6 (3.8)

31 (4.9)

 Former

28 (10.6)

31 (14.4)

20 (12.7)

79 (12.4)

 Never

81 (30.8)

93 (43.1)

35 (22.2)

209 (32.8)

 Unknown

140 (53.2)

81 (37.5)

97 (61.4)

318 (49.9)

Diabetes, n (%)

13 (4.9)

7 (3.2)

3 (1.9)

23 (3.6)

Hypertension, n (%)

56 (21.3)

40 (18.5)

25 (15.8)

121 (19.0)

Total cholesterol (mmol/L), mean (SD)

5.5 (1.0)

5.3 (1.0)

5.4 (1.0)

5.4 (1.0)

HDL cholesterol (mmol/L), mean (SD)

1.6 (0.5)

1.6 (0.5)

1.6 (0.5)

1.6 (0.5)

Systolic BP (mmHg), mean (SD)

121.1 (14.8)

122.2 (14.2)

122.1 (13.8)

121.7 (14.4)

Coronary artery disease, n (%)

0 (0.0)

0 (0.0)

2 (1.3)

2 (0.3)

Cerebrovascular or peripheral artery disease, n (%)

0 (0.0)

2 (0.9)

1 (0.6)

3 (0.5)

Aged ≥ 60 years

Placebo (n = 70)

Erenumab 70 mg (n = 38)

Erenumab 140 mg (n = 35)

Total (N = 143)

Age, mean (SD)a

62.0 (1.6)

62.1 (1.5)

61.7 (1.6)

61.9 (1.6)

Female, n (%)

55 (78.6)

31 (81.6)

27 (77.1)

113 (79.0)

Race, n (%)

 Asian

2 (2.9)

3 (7.9)

4 (11.4)

9 (6.3)

 White

65 (92.9)

33 (86.8)

31 (88.6)

129 (90.2)

BMI (kg/m2), mean (SD)

26.3 (4.8)

25.4 (5.6)

26.1 (4.9)

26.0 (5.0)

MMDs, mean (SD)

11.2 (5.5)

10.7 (5.3)

10.8 (3.7)

11.0 (5.0)

MMDs, categories, n (%)

 8–14 MMDs

36 (51.4)

22 (57.9)

22 (62.9)

80 (55.9)

 ≥ 15 MMDs

14 (20.0)

5 (13.2)

5 (14.3)

24 (16.8)

Medication overuse, n (%)b

 Yes

7 (10.0)

4 (10.5)

3 (8.6)

14 (9.8)

 No

13 (18.6)

3 (7.9)

5 (14.3)

21 (14.7)

PPTF, n (%)

 0

26 (37.1)

17 (44.7)

14 (40.0)

57 (39.9)

 1

11 (15.7)

7 (18.4)

4 (11.4)

22 (15.4)

 2

12 (17.1)

7 (18.4)

5 (14.3)

24 (16.8)

 ≥ 3

21 (30.0)

7 (18.4)

12 (34.3)

40 (28.0)

Framingham cardiovascular risk factors

Cigarette use, n (%)

 Current

3 (4.3)

0 (0.0)

0 (0.0)

3 (2.1)

 Former

15 (21.4)

4 (10.5)

3 (8.6)

22 (15.4)

 Never

20 (28.6)

24 (63.2)

9 (25.7)

53 (37.1)

 Unknown

32 (45.7)

10 (26.3)

23 (65.7)

65 (45.5)

Diabetes, n (%)

1 (1.4)

1 (2.6)

1 (2.9)

3 (2.1)

Hypertension, n (%)

19 (27.1)

6 (15.8)

9 (25.7)

34 (23.8)

Total cholesterol (mmol/L), mean (SD)

5.3 (1.1)

5.35 (0.8)

5.6 (1.0)

5.4 (1.0)

HDL cholesterol (mmol/L), mean (SD)

1.6 (0.4)

1.8 (0.5)

1.5 (0.4)

1.6 (0.5)

Systolic BP (mmHg), mean (SD)

124.1 (12.9)

120.6 (14.3)

124.2 (15.4)

123.2 (13.9)

Coronary artery disease, n (%)

1 (1.4)

0 (0.0)

0 (0.0)

1 (0.7)

Cerebrovascular or peripheral artery disease, n (%)

3 (4.3)

0 (0.0)

2 (5.7)

5 (3.5)

  1. Smoking-related information was not collected in the LIBERTY and EMPOwER studies. Hence, these were counted under the “Unknown” category in the parameter “Cigarette use”. Total cholesterol and HDL-related information was not collected in the LIBERTY study. Data were pooled from the Phase 2 CM (randomized analysis set), STRIVE (full analysis set), ARISE (full analysis set), LIBERTY (randomized analysis set), and EMPOwER (randomized analysis set) studies and are presented as mean (SD), unless stated
  2. Abbreviations: BMI Body mass index, BP Blood pressure, CM Chronic migraine, EM Episodic migraine, HDL High-density lipoprotein, MMD Monthly migraine days, PPTF Prior preventive treatment failure, SD Standard deviation
  3. aAlthough the inclusion criterion in all studies was age between 18 to 65 years, there was one patient aged 17 years and one aged 66 years in the data pool
  4. bMedication overuse was captured only for phase 2 CM study